Homocysteine Reduction and Vascular–Metabolic Changes During PCSK9 Inhibition in Familial Hypercholesterolemia:A Prospective Cohort Study

Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk, but their effects on homocysteine (Hcy) and broader vascular–metabolic pathways remain poorly characterized. Objective To evaluate changes in plasma Hcy and related vascular–metabolic biomarkers during PCSK9 inhibitor treatment in patients with familial hypercholesterolemia (FH). Methods In this prospective, single-center observational cohort study, 50 patients with FH initiating a PCSK9 inhibitor were evaluated at baseline and after 12 weeks. The primary endpoint was the within-subject change in plasma Hcy. Paired assessments included lipid parameters, urinary oxidative stress markers, biomarkers of the arginine–nitric oxide pathway, and ancillary untargeted metabolomic profiling. Results Mean Hcy decreased from 12.6 ± 6.7 to 8.9 ± 2.4 µmol/L, a 29% reduction, while median Hcy decreased from 10.7 µmol/L (IQR, 9.0–13.4) to 9.1 µmol/L (IQR, 7.0–10.5), a 15% reduction (P < 0.001). Hyperhomocysteinemia (> 15 µmol/L) resolved in all 10 affected patients (P = 0.002). Total cholesterol, corrected LDL-C, and lipoprotein(a) decreased by 37.9%, 34.1%, and 35.2%, respectively. Urinary F₂-isoprostanes, DH-isoprostanes, and dinor-isoprostane metabolites also decreased significantly, whereas arginine–nitric oxide pathway biomarkers did not. Multivariable analysis identified coordinated associations between ΔHcy and methylmalonic acid, arginine–nitric oxide metabolites, LDL-C reduction, and lipoprotein(a). Metabolomics showed sterol and phospholipid remodeling, lower choline abundance, and a higher putative betaine-related signal. Conclusion PCSK9 inhibition was associated with reduced Hcy, marked lipid remodeling, and lower oxidative stress in FH, supporting further investigation of Hcy as a treatment-responsive biomarker of broader vascular–metabolic remodeling. This response may help characterize vascular biology during intensive lipid-lowering therapy in high-risk FH.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11593797/v1
Primary Topic
Lipoproteins and Cardiovascular Health
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Homocysteine Reduction and Vascular–Metabolic Changes During PCSK9 Inhibition in Familial Hypercholesterolemia:A Prospective Cohort Study

Alessandro Di Minno, Roberta Baetta, Ilenia Lorenza Calcaterra, Matteo Nicola Dario Di Minno et al.
Research Square
Lipoproteins and Cardiovascular Health
preprint

Homocysteine Reduction and Vascular–Metabolic Changes During PCSK9 Inhibition in Familial Hypercholesterolemia:A Prospective Cohort Study

Alessandro Di Minno, Roberta Baetta, Ilenia Lorenza Calcaterra, Matteo Nicola Dario Di Minno, Gualtiero I. Colombo, Giuliana Fortunato, Gabriella Iannuzzo, Chiara Caputo, Paola Ciciola, Carmine De Luca, Maria Donata Di Taranto, Mauro Amato, Damiano Baldassarre, Daniela Coggi, Guido D’Errico, Antonella Tufano
preprint en

Abstract

Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk, but their effects on homocysteine (Hcy) and broader vascular–metabolic pathways remain poorly characterized. Objective To evaluate changes in plasma Hcy and related vascular–metabolic biomarkers during PCSK9 inhibitor treatment in patients with familial hypercholesterolemia (FH). Methods In this prospective, single-center observational cohort study, 50 patients with FH initiating a PCSK9 inhibitor were evaluated at baseline and after 12 weeks. The primary endpoint was the within-subject change in plasma Hcy. Paired assessments included lipid parameters, urinary oxidative stress markers, biomarkers of the arginine–nitric oxide pathway, and ancillary untargeted metabolomic profiling. Results Mean Hcy decreased from 12.6 ± 6.7 to 8.9 ± 2.4 µmol/L, a 29% reduction, while median Hcy decreased from 10.7 µmol/L (IQR, 9.0–13.4) to 9.1 µmol/L (IQR, 7.0–10.5), a 15% reduction (P < 0.001). Hyperhomocysteinemia (> 15 µmol/L) resolved in all 10 affected patients (P = 0.002). Total cholesterol, corrected LDL-C, and lipoprotein(a) decreased by 37.9%, 34.1%, and 35.2%, respectively. Urinary F₂-isoprostanes, DH-isoprostanes, and dinor-isoprostane metabolites also decreased significantly, whereas arginine–nitric oxide pathway biomarkers did not. Multivariable analysis identified coordinated associations between ΔHcy and methylmalonic acid, arginine–nitric oxide metabolites, LDL-C reduction, and lipoprotein(a). Metabolomics showed sterol and phospholipid remodeling, lower choline abundance, and a higher putative betaine-related signal. Conclusion PCSK9 inhibition was associated with reduced Hcy, marked lipid remodeling, and lower oxidative stress in FH, supporting further investigation of Hcy as a treatment-responsive biomarker of broader vascular–metabolic remodeling. This response may help characterize vascular biology during intensive lipid-lowering therapy in high-risk FH.

Research Square
Centro Cardiologico Monzino (IT), Federico II University Hospital (IT), CEINGE Biotecnologie Avanzate Franco Salvatore (Italy) (IT), University of Naples Federico II (IT)
Università degli Studi di Napoli Federico II
Good health and well-being
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon